Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.1152W HIGH $2.72
Volume
568.14 K
Value Traded
230.93 K
Short % Float
-
Days to Cover
1.0
-16.37%Week
-28.75%1 Month
-73.89%3 Month
-85.25%6 Month
-99.57%5 Year
-99.65%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
2.18 M
EPS (TTM)
-1.27
P/E Ratio
-
Ent. Value
8.75 M
Total Shares
20.12 M
Float Shares
-
Insiders
18.91%
Institutions
1.60%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
PoA blends historical approval base rates, trial design score and FDA review track record.
VVOS Catalyst Timeline
Dated clinical, regulatory and corporate events for Vivos Therapeutics, Inc.
Past FDA Catalysts and PDUFA Decisions
How VVOS actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| No matching catalysts | ||||||
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Vivos Therapeutics, Inc. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every VVOS program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| Vivos DNA appliance | pediatric obstructive sleep apnea | 2025-09-17 | 20 · 40% of pediatric patients · with symptoms recurring in up to a quarter of casesRead More | Vivos Therapeutics Announces Landmark Clinical Trial Results in Pediatric Obstructive Sleep Apnea TreatmentRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Skaff Michael C10% Owner | Buy | 859,166 859,166 held | $0.58 | 06/30/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in VVOS
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in VVOS for Q2 2026. | ||||
Ownership Trends
VVOS Short Interest
Shares sold short, counted twice a month.
-
Short % of Float
of tradable shares sold short
2.4M
Shares Sold Short
-17.7% vs prior count
1.0 Low
Days to Cover
trading days of normal volume to buy every short share back
2.4M
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How VVOS ranks across every disease it competes in
Competitive Position is a premium feature
See how VVOS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialVVOS News
VVOSCORRECTION: SOD Sciences Welcomes Vivos Therapeutics as Strategic Investor and Partner in the ReBalU Primed Cell Test
SOD Sciences has partnered with Vivos Therapeutics, with Vivos acquiring an 11% equity stake and shared ownership of key patents. This collaboration focuses on the ReBalU Primed Cell Test, which aims to identify chronic disease risks through a unique testing protocol. The partnership positions both companies to advance personalized medicine for chronic disease patients.
Read more →VVOSSOD Sciences Welcomes Vivos Therapeutics as Strategic Investor and Partner in the ReBalU Primed Cell Test
SOD Sciences has partnered with Vivos Therapeutics, which acquired an 11% equity stake and joint ownership of key patents. This collaboration focuses on the ReBalU Primed Cell Test, aimed at identifying chronic disease risks through pseudohypoxia. The partnership targets nearly 500,000 chronic disease patients, enhancing personalized medicine approaches.
Read more →VVOSVivos Therapeutics Reports Nasdaq Confirmation of Compliance with Continued Listing Shareholders’ Equity Standard
Vivos Therapeutics announced it is in compliance with Nasdaq's stockholders' equity requirement after acquiring an interest in SOD Sciences. The company expects this acquisition to boost its equity by more than $10 million. CEO R. Kirk Huntsman expressed satisfaction with the compliance confirmation and emphasized ongoing efforts to maintain compliance.
Read more →VVOSVivos Therapeutics Closes Acquisition of Stake in SOD Sciences and 50% Interest in Pseudohypoxia Test, Opening a Potential Path to Access More Than 325,000 New Patients Through the AHA Channel
Vivos Therapeutics has completed its acquisition of an 11% equity interest in SOD Sciences and a 50% stake in its pseudohypoxia test. This move is anticipated to enhance Vivos' market reach, providing access to over 325,000 patients through a partnership with American Health Associates. The transaction is expected to significantly boost stockholders' equity, although it is subject to final agreements and regulatory approvals.
Read more →VVOS▲ +6.6%on this newsshared move
Vivos Therapeutics Agrees to Acquire Minority Stake in SOD Sciences and 50% Interest in Proprietary Pseudohypoxia Test
Vivos Therapeutics has announced a definitive agreement to acquire an 11% equity interest in SOD Sciences and a 50% co-ownership of a proprietary pseudohypoxia test. The transaction, valued at $12 million in preferred stock, aims to enhance Vivos' market position and facilitate collaborations with the Cleveland Clinic and American Health Associates. The closing is contingent on customary conditions, including regulatory approvals.
Read more →VVOS▲ +12.2%on this news
Vivos Therapeutics Reports Progress in Material Cost Reductions and Revenue Growth Initiatives
Vivos Therapeutics has announced a restructuring plan aimed at saving $3.6 million annually, with immediate implementation of staff reductions and vendor changes. The company is also experiencing a surge in referrals and expects significant revenue growth from its EEG diagnostic testing and Remote Patient Monitoring initiatives. Management aims to achieve cash flow positivity by late 2026 or early 2027.
Read more →VVOSVivos Therapeutics Announces Material Debt Reduction
Vivos Therapeutics has announced a material reduction in its debt by exchanging outstanding principal for shares of common stock. This strategic move is expected to enhance the company's financial position by lowering liabilities and increasing stockholders' equity. The company continues to focus on innovative treatments for obstructive sleep apnea, which affects a significant portion of the adult population.
Read more →VVOS▼ -13%on this news· ran to -33% by day 3
Vivos Therapeutics and South Palm Cardiovascular Associates Sign Definitive Agreements to Launch Regional Sleep Testing and Treatment Center
Vivos Therapeutics has signed definitive agreements with South Palm Cardiovascular Associates to establish a regional Sleep & Airway Medicine Center in Palm Beach County, Florida. This collaboration aims to improve access to obstructive sleep apnea (OSA) treatment, leveraging Vivos' innovative technology. The center is expected to begin operations in early 2027, with a projected revenue of $6 million annually.
Read more →VVOSVivos Therapeutics Reports Record New Patient Referrals at its Nevada Sleep & Airway Medicine Centers
Vivos Therapeutics reported a remarkable 212% increase in new patient referrals at its Nevada Sleep & Airway Medicine Centers over the last six weeks. This surge coincides with the upcoming opening of a new facility in Henderson, expected to enhance operational capacity. CEO Kirk Huntsman highlighted the company's strategic changes aimed at capitalizing on this growth, anticipating significant revenue increases as patient care expands.
Read more →VVOSVivos Therapeutics Opens New Sleep Testing and Treatment Facility in Nevada to Meet Rapidly Growing Patient Demand for Sleep Apnea Testing and Treatment
Vivos Therapeutics has opened a new sleep testing and treatment facility in Henderson, Nevada, which is expected to more than double its annual revenue capacity to over $10 million. The facility will provide comprehensive care for obstructive sleep apnea, employing a specialized team to deliver advanced treatment options. This expansion comes in response to a significant increase in patient referrals in the Las Vegas market.
Read more →VVOS▼ -12.3%on this newsshared move
Vivos Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Update
Vivos Therapeutics reported a strong second quarter in 2026, with a 35% increase in revenue driven by rising patient demand for its obstructive sleep apnea treatments. The company has expanded its facilities and increased its provider count, leading to significant gains in patient referrals. However, operating losses have also increased, highlighting ongoing financial challenges.
Read more →VVOS▲ +12.4%on this newsshared move
Vivos Therapeutics Schedules Release of Second Quarter 2026 Financial Results and Conference Call
Vivos Therapeutics plans to release its second quarter 2026 financial results on August 14, 2026, followed by a conference call at 5:00 PM ET. The call will cover operational updates and strategic collaborations aimed at enhancing revenue. Vivos focuses on innovative treatments for obstructive sleep apnea, with FDA-cleared devices for various severity levels.
Read more →VVOS▼ -26.3%on this news
Vivos Therapeutics Announces Issuance of New US Patent Broadening Protection for Its Vivos CARE Oral Medical Device Technology
Vivos Therapeutics has announced the issuance of a new US patent that broadens protection for its Vivos CARE oral medical devices. This patent, along with a previously issued one, enhances the company's intellectual property position and strengthens its competitive edge in treating obstructive sleep apnea. The FDA has granted clearances for these devices, marking a significant achievement in the industry.
Read more →VVOS▼ -19.6%on this news
Vivos Therapeutics and Streeterville Extend Timeframe of Strategic Financing Agreement and Reaffirm Commitment to Convert Debt Into Common Stock and Perpetual Preferred Equity
Vivos Therapeutics has extended its strategic financing agreement with Streeterville Capital until August 31, 2026. This extension allows Vivos more time to raise necessary equity while reaffirming Streeterville's commitment to convert up to $4.5 million of debt into equity. The management believes this will facilitate a more organized capital-raising process.
Read more →VVOSVivos Therapeutics Announces Intent to File a Registration Statement for a Proposed Rights Offering
Vivos Therapeutics plans to file a registration statement for a proposed rights offering, aiming to distribute subscription rights to shareholders. The offering is contingent on SEC approval, with rights expected to be exercisable for nine months. Management highlights the potential for additional capital to support operations, though uncertainties remain regarding completion.
Read more →VVOSVivos Inc. Announces Receipt of Washington State Radioactive Materials License for IsoPet Manufacturing
Vivos Inc. has received its Washington State Radioactive Materials License for the manufacturing of IsoPet®, a development that marks a significant regulatory milestone for the company's animal health division. This license allows for in-house production at Vivos' new facility in Richland, Washington, facilitating the expansion of certified IsoPet® treatment centers nationwide. The company plans to quickly begin production and anticipates shipping its first units in the near future, enhancing access to precise cancer therapies for companion animals and horses.
Read more →VVOS▼ -8.8%on this newsshared move
Vivos Therapeutics Announces Key Collaboration Agreement with Multi-Location Florida Cardiology Group to Extend Much Needed Sleep Apnea and Insomnia Diagnosis and Treatment to Cardiovascular Patients
Vivos Therapeutics has entered a collaboration with South Palm Cardiovascular Associates to form AIM Florida, aimed at improving diagnosis and treatment for patients with obstructive sleep apnea and insomnia who also suffer from cardiovascular disease. This partnership seeks to enhance patient care and expand access to integrated services in Florida. Vivos anticipates that this model could be replicated across the country, although there are uncertainties regarding the finalization of agreements and operational execution.
Read more →VVOSVivos Therapeutics To Participate in the Small Cap Showcase & WTR Insights on June 9, 2026
Vivos Therapeutics will participate in The Small Cap Showcase & WTR Insights on June 9, 2026, in New York City. CEO Kirk Hunstman is set to deliver a corporate presentation and engage in one-on-one meetings with investors. This event aims to highlight investment opportunities among micro and small-cap companies.
Read more →VVOS▲ +24.8%on this newsshared move
Vivos Therapeutics Announces Binding Agreement for Senior Debt-to-Equity Exchange of Up to $4.5 Million from Streeterville Capital to Support Continued Nasdaq Listing
Vivos Therapeutics has announced a binding agreement with Streeterville Capital to convert up to $4.5 million of its senior debt into preferred and common stock. This transaction, aimed at improving the company's financial health, includes commitments to suspend repayment obligations temporarily. The success of this exchange relies on the completion of additional equity financings, which carries inherent risks. Overall, this initiative is part of Vivos' strategy to comply with Nasdaq listing standards and enhance liquidity.
Read more →VVOSVivos Therapeutics Reports First Quarter 2026 Financial Results and Provides Operational Update
Vivos Therapeutics reported a 70% year-over-year increase in revenue for Q1 2026, amounting to approximately $5.1 million. The firm attributed this growth primarily to its acquisition of The Sleep Center of Nevada and the successful implementation of its new business model. While gross profit also increased significantly, the company recorded a net loss of $7.8 million, attributed to rising operating expenses and the costs related to business expansion. Vivos emphasized its commitment to restructuring and improving cash flow as it works to solidify growth.
Read more →About Vivos Therapeutics, Inc.
Headquarters7921 SOUTHPARK PLAZA,, LITTLETON, CO, 80120
BIOPHARMAWATCH ELITE PLUS
Trade the next VVOS catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime